Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Regains Nasdaq Compliance After Private Placement

NEW YORK (GenomeWeb News) – Response Genetics said on Monday that it has regained compliance with a Nasdaq requirement calling for a minimum $35 million market value of listed securities.

The Los Angeles-based diagnostics firm said that Nasdaq notified it that it regained compliance on Oct. 5 and the delisting matter is now closed.

Nasdaq had notified Response Genetics in July of its non-compliance. Last month, the company raised $8.8 million in a private placement with a "significant" stockholder. Response Genetics later disclosed in a document filed with the US Securities and Exchange Commission that the investors in the placement are the Glaxo Group and Swiftcurrent Partners.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more